Metastatic Bone Disease Treatment Market Outlook - 2027
Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer cases are diagnosed each year. Approximately 50% of these tumors can spread (metastasize) to the skeleton. With improved medical treatment of many cancers especially breast, lung, and prostate patients are living longer. However, the primary cancers in more of these patients are spreading to bone. The tumors that result are called bone metastases. Some cancers do not readily spread to bone, while others do. MBD causes pain in the area of spread, damages and weakens bone, and puts the patient at a greater risk for broken bones. It can make it hard to participate in daily activities. The biggest concern for patients with MBD is the general loss in quality of life. Metastases to the lung and liver are often not detected until late in the course of disease because patients experience no symptoms. In contrast, bone metastases are generally painful when they occur. Because MBD weakens the affected bones, people with the disease are prone to fractures. Broken bones caused by MBD are termed "pathological fractures."
Covid-19 Scenario analysis:
The Covid outbreak across the world has landed cancer patients in grave danger. Worried about their low immunity levels, leading hospitals and research centres are advising cancer patients to remain at home till Covid infections die out. Deferment of surgeries, radiation and chemotherapy sessions have messed up the treatment schedules of many cancer patients across the globe. Patients who are undergoing cancer treatment may have low immunity, and are more susceptible to catching the infection. And if it does, it’ll be very fatal for the patient. So Doctors taking all precautions to keep them safe – at least from Covid. The immunity of the Cancer patients needs to be driven up by giving them the required treatment hence the market is steady but might have some inconvenience because of supply and manufacturing of drugs being low during the pandemic.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:
Increased prevalence of cancer:
More than 1.2 million new cancer cases are diagnosed each year. Approximately 50% of these tumors can spread (metastasize) to the skeleton. Bone is a frequent site of metastases and typically indicates a short-term prognosis in cancer patients. Once cancer has spread to the bones it can rarely be cured, but often it can still be treated to slow its growth. The majority of skeletal metastases are due to breast and prostate cancer. Bone metastasis is actually much more common than primary bone cancers, especially in adults. The diagnosis is based on signs, symptoms and imaging. Through the advances of modern cancer treatment options, there is a general improvement in the longevity of cancer patients, and hence an increase in the risk of bone metastasis New classes of drugs and new interventions are given a better quality of life to these patients and improved the expectancy of life. It is necessary a multidisciplinary approach to treat patients with bone metastasis. In this paper we review the types, clinical approach and treatment of bone metastases. Metastasize is a process that involves loss of intercellular cohesion, cell migration, angiogenesis, access to systemic circulation, survival in circulation, evasion of local immune responses, and growth at distant organs. Bone is the third most frequent site of metastasis, behind lung and liver. Prostate and breast cancer (BC) are responsible for the majority of the skeletal metastases (up to 70%). This reflects both the high incidence and relatively long clinical course of these tumours.
Technological advancements in treatment:
Over the past decades there has been an increase in the incidence of cancer worldwide. With the advancement in treatment, patient survival has improved in tandem with the increasing incidence. This, together with the availability of advanced modern diagnostic modalities, has resulted in more cases of metastatic bone disease being identified. Bone metastasis is an ongoing problem and has significant morbidity implications for patients affected. Multimodal treatment strategies are required in dealing with metastatic bone disease, which include both surgical and non-surgical treatment options. In the multidisciplinary team, orthopaedic surgeons play an important role in improving the quality of life of cancer patients. Surgical intervention in this setting is aimed at pain relief, restoration of function and improvement in functional independence. In selected cases with respectable solitary metastasis, surgical treatment may be curative. With the advancement of surgical technique and improvement in implant design and manufacture, a vast array of surgical options are available in the modern orthopaedic arena. In the majority of cases, limb salvage procedures have become the standard of care in the treatment of metastatic bone disease. Non-surgical adjuvant treatment also contributes significantly to the improvement of cancer patient care. In the current modern orthopaedic surgery arena, complex reconstructive surgery is made possible with the availability of advanced implant technology. Through better understanding of biomechanics and tribology, as well as better implant manufacturing processes, orthopaedic surgeons now have a wide array of reliable implant options. A multidisciplinary approach in this setting is gaining paramount importance resulting in metastatic bone disease treatment market growth.
The management of patients with metastatic bone disease requires a multidisciplinary approach to ensure thorough diagnostic workup and treatment planning. A multi-modal treatment strategy, which includes medical therapy, radiotherapy and surgery, is encouraged in order to optimize treatment outcomes. In the setting of metastatic disease, surgical treatment is aimed at alleviating pain, restoring functional independence, and improving the overall quality of life of patients such complications and high treatment charges can cause restrain in market
Key benefits of the report:
- This study presents the analytical depiction of the global Metastatic bone disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Metastatic bone disease treatment market share.
- The current market is quantitatively analyzed to highlight the global Metastatic bone disease treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Metastatic bone disease treatment market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Metastatic bone disease treatment Market research report:
- What are the leading market players active in the Metastatic bone disease treatment market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Metastatic Bone Disease Treatment Market Report Highlights
By Treatment Type
By End User
Key Market Players
Hoffmann-La Roche AG,, Novartis AG,, Amgen Inc.,, Eli Lilly and Company,, Merck & Co., Inc.,, Bayer AG,, Pfizer Inc.,, Allergan plc., Radius Health, Inc.,, Teva Pharmaceutical Industries Ltd.,